A detailed history of Mason & Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mason & Associates Inc holds 655 shares of VRTX stock, worth $284,283. This represents 0.05% of its overall portfolio holdings.

Number of Shares
655
Holding current value
$284,283
% of portfolio
0.05%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 06, 2025

BUY
$366.54 - $479.53 $240,083 - $314,092
655 New
655 $256,000
Q4 2021

Mar 18, 2022

BUY
$177.01 - $223.45 $194,179 - $245,124
1,097 New
1,097 $241,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mason & Associates Inc Portfolio

Follow Mason & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mason & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mason & Associates Inc with notifications on news.